Cancer Growth Inhibitors Market & Clinical Pipeline Analysis
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.
Pharmaceutical industry consists of various products for cancer treatment and several years of research along with significant investments have helped in developing many innovative products. Every year, new cancer therapeutic belonging to different drug category is introduced across the globe. Cancer growth inhibitors are recent additions as compared to conventional therapeutics which have modest pharmacological potential. Pharmaceutical companies have been able to introduce newer cancer growth inhibitors for different cancer categories to overcome therapeutic and commercialization barriers. Due to higher investments in research and development, their clinical pipeline is becoming stronger and novel cancer growth inhibitors for different cancers are entering in global market. Their rate of market introduction is expected to increase in coming years due to technological advancements and increased funding. Consequently, market introduction of these cancer growth inhibitors is expected to offer severe competition to existing cancer therapeutics in global market.
Cancer growth inhibitors market shows overlapping boundaries due to which it becomes difficult to demarcate different categories. For instance, a tyrosine kinase may be a small molecules or a large molecule because they have same inhibitory molecule. On the other hand, they may inhibit cellular processes and belong to different molecular classes. Despite these differences, cancer growth inhibitors occupy large market shares and targeted therapeutics seems to be the major contenders. They have high safety and efficacy profiles along with minimized side effects due to which large number of patients are including them as a part of their regular therapeutic regime. In coming years, they are expected to become main focus of pharmaceutical companies because conventional cancer therapies like chemotherapy have proved to have modest efficacy. In future, their therapeutic efficacy is expected to increase and many innovative products are at different phases of clinical development due to which their global market is expected to witness steady growth.
Clinical pipeline of cancer growth inhibitors is increasing due to innovations and potential competition from newly developed cancer drugs. Pharmaceutical companies are focusing on approaches like utilization of next generation sequencing and computerized simulation to prevent undue wastage of time and resources. Relapse is another biggest issues associated with conventional cancer therapeutics which could be prevented with the help of cancer growth inhibitors. Innovative cancer growth inhibitors are expected to increase average survival time and decrease mortality rates. These factors are expected to increase the demand for cancer growth inhibitors but still lots of modalities have to be streamlined in order to offer sustainable competition to newly coming cancer therapeutics belonging to other drug categories. One of the major steps in order to overcome these shortcomings could be the utilization of high end technology.
Cancer Growth Inhibitors Covered in Report:
Pharmaceutical industry consists of various products for cancer treatment and several years of research along with significant investments have helped in developing many innovative products. Every year, new cancer therapeutic belonging to different drug category is introduced across the globe. Cancer growth inhibitors are recent additions as compared to conventional therapeutics which have modest pharmacological potential. Pharmaceutical companies have been able to introduce newer cancer growth inhibitors for different cancer categories to overcome therapeutic and commercialization barriers. Due to higher investments in research and development, their clinical pipeline is becoming stronger and novel cancer growth inhibitors for different cancers are entering in global market. Their rate of market introduction is expected to increase in coming years due to technological advancements and increased funding. Consequently, market introduction of these cancer growth inhibitors is expected to offer severe competition to existing cancer therapeutics in global market.
Cancer growth inhibitors market shows overlapping boundaries due to which it becomes difficult to demarcate different categories. For instance, a tyrosine kinase may be a small molecules or a large molecule because they have same inhibitory molecule. On the other hand, they may inhibit cellular processes and belong to different molecular classes. Despite these differences, cancer growth inhibitors occupy large market shares and targeted therapeutics seems to be the major contenders. They have high safety and efficacy profiles along with minimized side effects due to which large number of patients are including them as a part of their regular therapeutic regime. In coming years, they are expected to become main focus of pharmaceutical companies because conventional cancer therapies like chemotherapy have proved to have modest efficacy. In future, their therapeutic efficacy is expected to increase and many innovative products are at different phases of clinical development due to which their global market is expected to witness steady growth.
Clinical pipeline of cancer growth inhibitors is increasing due to innovations and potential competition from newly developed cancer drugs. Pharmaceutical companies are focusing on approaches like utilization of next generation sequencing and computerized simulation to prevent undue wastage of time and resources. Relapse is another biggest issues associated with conventional cancer therapeutics which could be prevented with the help of cancer growth inhibitors. Innovative cancer growth inhibitors are expected to increase average survival time and decrease mortality rates. These factors are expected to increase the demand for cancer growth inhibitors but still lots of modalities have to be streamlined in order to offer sustainable competition to newly coming cancer therapeutics belonging to other drug categories. One of the major steps in order to overcome these shortcomings could be the utilization of high end technology.
Cancer Growth Inhibitors Covered in Report:
- Cancer Tyrosine Kinase
- Proteasome Inhibitors
- MTOR Protein Inhibitors
- Histone Deacetylase Inhibitors (HDAC inhibitors)
- PI3k
- Introduction & Classification of Cancer Growth Inhibitors
- Cancer Growth Inhibitors Clinical Pipeline by Company, Indication & Phase
- Cancer Growth Inhibitors Clinical Pipeline: 629 Drugs
- Markets Cancer Growth Inhibitors: 48 Drugs
- Tyrosine Kinase Dominates Cancer Growth Inhibitors Pipeline: 394 Drugs
- HDAC Inhibitors Clinical Pipeline: 65 Drugs
- MTOR Protein Inhibitors Clinical Pipeline: 62 Drugs
- PI3k Clinical Pipeline: 89 Drugs
- Proteasome Inhibitors Clinical Pipeline: 19 Drugs
- Global Cancer Growth Inhibitors Market Future Prospects
1. INTRODUCTION TO CANCER GROWTH INHIBITORS
2. CLASSIFICATION OF CANCER GROWTH INHIBITORS
3. CANCER GROWTH INHIBITORS MECHANISM
4. GLOBAL CANCER GROWTH INHIBITORS MARKET OVERVIEW
4.1 Current Market Scenario
4.2 Cancer Growth Inhibitors Clinical Pipeline Overview
5. GLOBAL CANCER GROWTH INHIBITORS MARKET DYNAMICS
5.1 Favorable Market Parameters
5.2 Commercialization Challenges
6. GLOBAL CANCER GROWTH INHIBITORS MARKET FUTURE PROSPECTS
7. CANCER TYROSINE KINASE CLINICAL INSIGHT BY COMPANY, INDICATION & PHASE
7.1 Unknown
7.2 Research
7.3 Preclinical
7.4 Clinical
7.5 Phase-I
7.6 Phase-I/II
7.7 Phase-II
7.8 Phase-II/III
7.9 Phase-III
7.10 Preregistration
7.11 Registered
8. MARKETED CANCER TYROSINE KINASE CLINICAL INSIGHT
9. HDAC INHIBITORS CLINICAL INSIGHT BY COMPANY, INDICATION & PHASE
9.1 Research
9.2 Preclinical
9.3 Phase-I
9.4 Phase-I/II
9.5 Phase-II
9.6 Phase-III
9.7 Registered
10. MARKETED HDAC INHIBITORS CLINICAL INSIGHT BY COMPANY & INDICATION
11. MTOR PROTEIN INHIBITORS CLINICAL INSIGHT BY COMPANY, INDICATION & PHASE
11.1 Research
11.2 Preclinical
11.3 Clinical
11.4 Phase-I
11.5 Phase-I/II
11.6 Phase-II
11.7 Phase-III
11.8 Preregistration
11.9 Registered
12. MARKETED MTOR PROTEIN INHIBITORS CLINICAL INSIGHT BY COMPANY & INDICATION
13. PI3K INHIBITORS CLINICAL INSIGHT BY COMPANY, INDICATION & PHASE
13.1 Research
13.2 Preclinical
13.3 Phase-I
13.4 Phase-I/II
13.5 Phase-II
13.6 Phase-II/III
13.7 Phase-III
14. MARKETED PI3K INHIBITORS CLINICAL INSIGHT BY COMPANY & INDICATION
15. PROTEASOME INHIBITORS CLINICAL INSIGHT BY COMPANY, INDICATION & PHASE
15.1 Research
15.2 Preclinical
15.3 Phase-I
15.4 Phase-I/II
15.5 Phase-II
15.6 Phase-III
16. MARKETED PROTEASOME INHIBITORS CLINICAL INSIGHT BY COMPANY & INDICATION
17. COMPETITIVE LANDSCAPE
17.1 Advaxis
17.2 Amgen
17.3 AstraZeneca
17.4 Bristol Mayer Squibb
17.5 Celldex Therapeutics
17.6 Eli Lily
17.7 GalaxoSmithKline
17.8 Genetech
17.9 ImmunoCellular Therapeutics
17.10 ImmunoGen
17.11 Merck
17.12 Novartis
17.13 Pfizer
17.14 Roche
17.15 Sanofi
17.16 Teva
2. CLASSIFICATION OF CANCER GROWTH INHIBITORS
3. CANCER GROWTH INHIBITORS MECHANISM
4. GLOBAL CANCER GROWTH INHIBITORS MARKET OVERVIEW
4.1 Current Market Scenario
4.2 Cancer Growth Inhibitors Clinical Pipeline Overview
5. GLOBAL CANCER GROWTH INHIBITORS MARKET DYNAMICS
5.1 Favorable Market Parameters
5.2 Commercialization Challenges
6. GLOBAL CANCER GROWTH INHIBITORS MARKET FUTURE PROSPECTS
7. CANCER TYROSINE KINASE CLINICAL INSIGHT BY COMPANY, INDICATION & PHASE
7.1 Unknown
7.2 Research
7.3 Preclinical
7.4 Clinical
7.5 Phase-I
7.6 Phase-I/II
7.7 Phase-II
7.8 Phase-II/III
7.9 Phase-III
7.10 Preregistration
7.11 Registered
8. MARKETED CANCER TYROSINE KINASE CLINICAL INSIGHT
9. HDAC INHIBITORS CLINICAL INSIGHT BY COMPANY, INDICATION & PHASE
9.1 Research
9.2 Preclinical
9.3 Phase-I
9.4 Phase-I/II
9.5 Phase-II
9.6 Phase-III
9.7 Registered
10. MARKETED HDAC INHIBITORS CLINICAL INSIGHT BY COMPANY & INDICATION
11. MTOR PROTEIN INHIBITORS CLINICAL INSIGHT BY COMPANY, INDICATION & PHASE
11.1 Research
11.2 Preclinical
11.3 Clinical
11.4 Phase-I
11.5 Phase-I/II
11.6 Phase-II
11.7 Phase-III
11.8 Preregistration
11.9 Registered
12. MARKETED MTOR PROTEIN INHIBITORS CLINICAL INSIGHT BY COMPANY & INDICATION
13. PI3K INHIBITORS CLINICAL INSIGHT BY COMPANY, INDICATION & PHASE
13.1 Research
13.2 Preclinical
13.3 Phase-I
13.4 Phase-I/II
13.5 Phase-II
13.6 Phase-II/III
13.7 Phase-III
14. MARKETED PI3K INHIBITORS CLINICAL INSIGHT BY COMPANY & INDICATION
15. PROTEASOME INHIBITORS CLINICAL INSIGHT BY COMPANY, INDICATION & PHASE
15.1 Research
15.2 Preclinical
15.3 Phase-I
15.4 Phase-I/II
15.5 Phase-II
15.6 Phase-III
16. MARKETED PROTEASOME INHIBITORS CLINICAL INSIGHT BY COMPANY & INDICATION
17. COMPETITIVE LANDSCAPE
17.1 Advaxis
17.2 Amgen
17.3 AstraZeneca
17.4 Bristol Mayer Squibb
17.5 Celldex Therapeutics
17.6 Eli Lily
17.7 GalaxoSmithKline
17.8 Genetech
17.9 ImmunoCellular Therapeutics
17.10 ImmunoGen
17.11 Merck
17.12 Novartis
17.13 Pfizer
17.14 Roche
17.15 Sanofi
17.16 Teva
LIST OF FIGURES
Figure 1-1: Benefits of Cancer Growth Inhibitors
Figure 1-2: Functions of Cancer Growth Inhibitors
Figure 1-3: Improvement Required for Cancer Growth Inhibitor
Figure 2-1: Cancer Growth Inhibitors Classification
Figure 2-2: Different Cancer Growth Inhibitors on the Basis of their Targets
Figure 3-1: Generalized Working of Cancer Growth Inhibitors
Figure 3-2: Mechanism of Bortezomib
Figure 3-3: Mechanism of Vismodegib
Figure 3-4: Mechanism of Everolimus
Figure 3-5: Mechanism of Bevacizumab
Figure 3-6: Mechanism of Imatinib
Figure 4-1: Cancer Growth Inhibitors Pipeline by Phase(%), 2015
Figure 4-2: Cancer Growth Inhibitors Pipeline by Phase (Number), 2015
Figure 4-3: Cancer Tyrosine Kinase Disease Pipeline by Phase (%), 2015
Figure 4-4: Cancer Tyrosine Kinase Disease Pipeline by Phase (Numbers), 2015
Figure 4-5: HDAC Pipeline by Phase (%), 2015
Figure 4-6: HDAC Pipeline by Phase (Number), 2015
Figure 4-7: Discontinued HDAC Pipeline by Phase (%), 2015
Figure 4-8: Discontinued HDAC Pipeline by Phase (Number), 2015
Figure 4-9: MTOR Protein Inhibitors Pipeline by Phase (%), 2015
Figure 4-10: MTOR Protein Inhibitors Pipeline by Phase (Number), 2015
Figure 4-11: Discontinued MTOR Protein Inhibitors Pipeline by Phase (%), 2015
Figure 4-12: Discontinued MTOR Protein Inhibitors Pipeline by Phase (Number), 2015
Figure 4-13: PI3K Pipeline by Phase (%), 2015
Figure 4-14: PI3K Pipeline by Phase (Number), 2015
Figure 4-15: Discontinued PI3K Pipeline by Phase (%), 2015
Figure 4-16: Discontinued PI3K Pipeline by Phase (Number), 2015
Figure 4-17: Proteasome Inhibitors Pipeline by Phase (%), 2015
Figure 4-18: Proteasome Inhibitors Pipeline by Phase (Number), 2015
Figure 4-19: No Development Reported Proteasome Inhibitors Pipeline by Phase (%), 2015
Figure 4-20: No Development Reported Proteasome Inhibitors Pipeline by Phase (Number), 2015
Figure 5-1: Global Cancer Growth Inhibitors Market Favorable Parameters
Figure 5-2: Cancer Growth Inhibitors Market Commercialization Challenges
Figure 17-1: Advaxis Clinical Pipeline
Figure 17-2: Celldex Therapeutics Clinical Pipeline
Figure 17-3: ImmunoCellular Therapeutics Clinical Pipeline
Figure 17-4: ImmunoGen Clinical Pipeline
Figure 1-1: Benefits of Cancer Growth Inhibitors
Figure 1-2: Functions of Cancer Growth Inhibitors
Figure 1-3: Improvement Required for Cancer Growth Inhibitor
Figure 2-1: Cancer Growth Inhibitors Classification
Figure 2-2: Different Cancer Growth Inhibitors on the Basis of their Targets
Figure 3-1: Generalized Working of Cancer Growth Inhibitors
Figure 3-2: Mechanism of Bortezomib
Figure 3-3: Mechanism of Vismodegib
Figure 3-4: Mechanism of Everolimus
Figure 3-5: Mechanism of Bevacizumab
Figure 3-6: Mechanism of Imatinib
Figure 4-1: Cancer Growth Inhibitors Pipeline by Phase(%), 2015
Figure 4-2: Cancer Growth Inhibitors Pipeline by Phase (Number), 2015
Figure 4-3: Cancer Tyrosine Kinase Disease Pipeline by Phase (%), 2015
Figure 4-4: Cancer Tyrosine Kinase Disease Pipeline by Phase (Numbers), 2015
Figure 4-5: HDAC Pipeline by Phase (%), 2015
Figure 4-6: HDAC Pipeline by Phase (Number), 2015
Figure 4-7: Discontinued HDAC Pipeline by Phase (%), 2015
Figure 4-8: Discontinued HDAC Pipeline by Phase (Number), 2015
Figure 4-9: MTOR Protein Inhibitors Pipeline by Phase (%), 2015
Figure 4-10: MTOR Protein Inhibitors Pipeline by Phase (Number), 2015
Figure 4-11: Discontinued MTOR Protein Inhibitors Pipeline by Phase (%), 2015
Figure 4-12: Discontinued MTOR Protein Inhibitors Pipeline by Phase (Number), 2015
Figure 4-13: PI3K Pipeline by Phase (%), 2015
Figure 4-14: PI3K Pipeline by Phase (Number), 2015
Figure 4-15: Discontinued PI3K Pipeline by Phase (%), 2015
Figure 4-16: Discontinued PI3K Pipeline by Phase (Number), 2015
Figure 4-17: Proteasome Inhibitors Pipeline by Phase (%), 2015
Figure 4-18: Proteasome Inhibitors Pipeline by Phase (Number), 2015
Figure 4-19: No Development Reported Proteasome Inhibitors Pipeline by Phase (%), 2015
Figure 4-20: No Development Reported Proteasome Inhibitors Pipeline by Phase (Number), 2015
Figure 5-1: Global Cancer Growth Inhibitors Market Favorable Parameters
Figure 5-2: Cancer Growth Inhibitors Market Commercialization Challenges
Figure 17-1: Advaxis Clinical Pipeline
Figure 17-2: Celldex Therapeutics Clinical Pipeline
Figure 17-3: ImmunoCellular Therapeutics Clinical Pipeline
Figure 17-4: ImmunoGen Clinical Pipeline
